Monte Rosa Q2 2022 net loss $26.5M; IND submitted for MRT-2359

Monte Rosa Therapeutics, Inc.

Net loss of $26.5M for Q2 2022, compared to $18.4M in Q2 2021.
Cash, equivalents, and marketable securities of $299.5M as of June 30, 2022; expected runway into late 2024.
R&D expenses of $20.9M in Q2 2022 vs $14.6M in Q2 2021, driven by MRT-2359 advancement and platform expansion.
Submitted IND for MRT-2359 (GSPT1 degrader) for Myc-driven solid tumors; Phase 1/2 trial planned for Q4 2022.
Progress on CDK2 and NEK7 programs toward development candidate nominations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.